ライフサイエンスコーパス: proteosome

1 iquitinated protein(s) to be degraded by the proteosome.

2 nd degradation of both proteins via the 26 S proteosome.

3 nomeric C and B subunits are degraded by the proteosome.

4 ys limited stability, and is degraded by the proteosome.

5 ssential for its targeted degradation by the proteosome.

6 no other evidence for the involvement of the proteosome.

7 its susceptibility to proteolysis by the 26S proteosome.

8 cuolar proteolysis and is independent of the proteosome.

9 ination controls its degradation via the 26S proteosome.

10 1 and at the post-translational level by the proteosome.

11 get of ubiquitin-mediated degradation by the proteosome.

12 erruptus for degradation by Cullin-3 and the proteosome.

13 es ABHD5 by retarding its degradation by the proteosome.

14 y cysteine protease activity rather than the proteosome.

15 Janus kinase (JAK) 1/2 were degraded by the proteosome.

16 itive to pharmacologic inhibition of the 26S proteosome.

17 cytosolic degradation of heavy chains by the proteosomes.

18 esponses than alum-adjuvanted toxoid without proteosomes.

19 ) titers when the toxoid was formulated with proteosomes.

20 gradation, mediated in part by lysosomes and proteosomes.

21 oreover, it efficiently colocalizes with the proteosome 20s subunit, which degrades proteins into pep

22 and specifically inhibits chymotrypsin-like proteosome activity at low concentrations (< 100 nM) and

23 (FPA-137) was the most potent and inhibited proteosome activity in intact human prostate cancer PC-3

24 n of RON protein is blocked by inhibitors of proteosome activity.

25 eir functions, oppose the yeast ribosome and proteosome, along with evidence for the inverse transcri

26 aip-1 acts via binding to the proteosome and enhancing proteosomal function.

27 ing, small nucleolar RNAs, and the ubiquitin-proteosome and lysosome degradation pathways.

28 Although the proteosome and lysosome have been proposed to play a rol

29 ing ENaC channels, we used inhibitors of the proteosome and measured sodium channel activity.

30 ricus, including subunits of the thermosome, proteosome and ribosome, are acetylated at the N-terminu

31 catenin is ubiquitinated and degraded by the proteosome and that beta-catenin stability is regulated

32 with the capacity to interact with both the proteosome and ubiquitin ligases, in regulating nicotine

33 Translational, ubiquitin-proteosome, and endoplasmic reticulum-to-Golgi transport

34 o-gp160 formulated with liposomes plus MPL, proteosomes, and proteosomes plus emulsomes.

35 Moreover, the proteosome- and calpain-mediated protein degradation pat

36 tion of SNC1 by CPR1 is dependent on the 26S proteosome as a protease inhibitor MG132 stabilizes SNC1

37 protein folding (chaperones), the ubiquitin-proteosome, axon transport and NDD-specific genes in ser

38 eripheral activation of microglia by a nasal proteosome-based adjuvant (Protollin) that has been give

39 Here we show that nasal vaccination with a proteosome-based adjuvant that is well tolerated in huma

40 patibility complex (MHC) class I binding and proteosome cleavage site algorithms identified 101 influ

41 s in PR-DUB, INO80 chromatin remodelling and proteosome complexes.

42 tly posttranslational, mediated by ubiquitin-proteosome degradation as lactacystin, a proteosome inhi

43 h a reduction in Akt transcription, enhanced proteosome degradation of Akt, and altered levels of DJ-

44 r N-acetyl-Leu-Leu-norleucinal, which blocks proteosome degradation of IkappaB, demonstrating that NF

45 t the failure of NMJ function, activation of proteosome degradation, and a reduction of the Akt pathw

46 sequences, motifs associated with ubiquitin/proteosome degradation, that overlap the previously iden

47 tizyme targets ODC for ubiquitin-independent proteosome degradation, thereby inhibiting polyamine syn

48 ates inflammation and HIV transcription, for proteosome degradation.

49 ygen (O2) availability are also targeted for proteosome-dependent degradation by the E3 ubiquitin lig

50 cadherin transcriptional repressor Snail and proteosome-dependent degradation of beta-catenin protein

51 d inhibits the ubiquitination and subsequent proteosome-dependent degradation of p53.

52 t MCL-1 protein levels rapidly decrease in a proteosome-dependent fashion, whereas those of BCL-2 are

53 otal cellular Akt protein was decreased in a proteosome-dependent manner.

54 nslocated into the cytosol and degraded in a proteosome-dependent manner.

55 ssembled AAV5 capsid proteins and Rep52 in a proteosome-dependent manner.

56 inase (CDK) inhibitor p21(WAF1) protein in a proteosome-dependent manner.

57 26-I278T complex is degraded via a ubiquitin/proteosome-dependent mechanism.

58 tion of PTEN was most likely mediated by the proteosome-dependent pathway, we have evidence that PTEN

59 d in ubiquitin-mediated degradation in a 26S-proteosome-dependent pathway.

60 tinal secretions, whereas the toxoid without proteosomes did not.

61 that can target proteins for degradation by proteosomes during mitosis.

62 These may be triggered by proteosome dysfunction, as we find that this event links

63 Formulations of o-gp160 with MPL-AF, proteosomes, emulsomes, or proteosomes plus emulsomes el

64 izing Ab in lung wash, and formulations with proteosomes, emulsomes, or proteosomes plus emulsomes el

65 aining monophosphoryl lipid A (MPL), MPL-AF, proteosomes, emulsomes, or proteosomes with emulsomes el

66 and greatly accelerating its degradation by proteosomes following its ubiquitination by the E1B-55K/

67 e of JAK2 and by targeting bound JAK2 to the proteosome for degradation.

68 oxin B subunit with or without holotoxin, or proteosomes from Neisseria meningitidis outer membrane p

69 presentation to CD8(+) T cells is limited to proteosome-generated peptides from intracellular pathoge

70 ed with meningococcal outer membrane protein proteosomes has previously been shown to be immunogenic

71 nodeficiency virus (HIV) rgp160 complexed to proteosomes improved anti-gp160 serum IgA and IgG titers

72 a p23Skp1-dependent step and degraded by the proteosome in a ubiquitin-dependent step.

73 Alternate splicing generates the complex proteosome in eukaryotic cells.

74 Possible roles of the proteosome in Glu-mediated signaling in plants is discus

75 ger, naturally occurring peptide p2Cb by 20S proteosomes in vitro.

76 xed to meningococcal outer membrane proteins-proteosomes-in normal, healthy adults.

77 ion, altered glycosylation, degradation by a proteosome-independent pathway, and partial retention in

78 with the hexavalent vaccine formulated with proteosomes indicated the presence of hexavalent protein

79 Interestingly, MOMP proteosomes induce cytokine secretion in endocervical ep

80 by a variety of stresses including dopamine, proteosome inhibition and a pro-apoptopic stimulus.

81 Proteosome inhibition confirmed that reduced p53 protein

82 Proteosome inhibition does not appear to be the mechanis

83 ue from the dominant effect, as did the 26 S proteosome inhibitor ALLN.

84 thway and thus maturation was blocked by the proteosome inhibitor benzyloxycarbonyl-isoleucyl-glutamy

85 The proteosome inhibitor bortezomib (BTZ) induces endoplasmi

86 When ABT-737 was combined with the proteosome inhibitor bortezomib or CDK inhibitor purvala

87 degradation of CTR1 can be blocked with the proteosome inhibitor bortezomib, and this increases the

88 nti-IgG antibody, hydrogen peroxide, and the proteosome inhibitor bortezomib.

89 nsfectants were grown in the presence of the proteosome inhibitor clasto-lactacystin beta-lactone, su

90 ALLN (N-acetyl-Leu-Leu-norleucinal) and the proteosome inhibitor lactacystin inhibited the HRG-induc

91 Furthermore, co-treatment with H7 and the proteosome inhibitor LLnL prevented the accumulation of

92 However, treatment with the proteosome inhibitor MG-132 inhibited NF-kappaB activati

93 oth proteins was seen in the presence of the proteosome inhibitor MG-132 suggesting that they are nor

94 )), but not total p65, was unaffected by the proteosome inhibitor MG-132, which blocks IkappaB protei

95 tion of reduced GhCesA1 ZnBD is inhibited by proteosome inhibitor MG132 and also by E64 and EGTA, sug

96 Proteosome inhibitor MG132 and lentiviruses enabling ind

97 ied by treatment of wild-type roots with the proteosome inhibitor MG132 or the gibberellic acid (GA)

98 nse and was blocked by pretreatment with the proteosome inhibitor MG132.

99 Experiments with the proteosome inhibitor N-acetyl-Leu-Leu-norleucinal (ALLN)

100 ssociated degradation (ERAD) pathway using a proteosome inhibitor resulted in marked neutropenia in G

101 -341 (bortezomib) is a potent and reversible proteosome inhibitor that functions to degrade intracell

102 NF-kappa B activation; however, the specific proteosome inhibitor, lactacystin, failed to do so.

103 tin-proteosome degradation as lactacystin, a proteosome inhibitor, reverses these effects.

104 or, N-acetyl-leucyl-leucyl-methional, or the proteosome inhibitor, Streptomyces metabolite, lactacyst

105 ct is abrogated by treatment of cells with a proteosome inhibitor, suggesting that CHK2(R145W) is tar

106 olysis of ATF4, which can be blocked using a proteosome inhibitor.

107 EFs is stabilized by treatment with MG132, a proteosome inhibitor.

108 Pretreatment with the proteosome inhibitors ALLN, lactacystin, and PSI [N-benz

109 SRY protein expression was increased by proteosome inhibitors and by the androgen-liganded AR in

110 inhibition of IKK alpha or IKK beta, whereas proteosome inhibitors instead suppress NF-kappaB functio

111 ed degradation of HIF-1alpha was reversed by proteosome inhibitors lactacystin and MG-132.

112 o paxillin and treatment of the neurons with proteosome inhibitors prevented paxillin down-regulation

113 nsferase inhibitors, histone deacetylase and proteosome inhibitors, antiangiogenesis agents, Fms-like

114 e Cdk inhibitor roscovitine was prevented by proteosome inhibitors, indicating that Cdk1 stabilizes A

115 merase II inhibitors, kinase inhibitors, and proteosome inhibitors, induced functional activation of

116 emonstrate here that treatment with the 26 S proteosome inhibitors, MG132 and ALLN, leads to detectio

117 e with DSBs were restored in the presence of proteosome inhibitors, or when cells from the suspension

118 ely resembles cellular responses elicited by proteosome inhibitors, with rapid induction of heat shoc

119 ors administered in a suboptimal sequence or proteosome inhibitors.Oncogene advance online publicatio

120 lpha3 subunit draws the receptor subunit and proteosome into a complex.

121 ves degradation of cytosolic proteins by the proteosome into peptides, transport of the peptides acro

122 has structural similarity to the cytoplasmic proteosome is increased in leukemic cells from approxima

123 se inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduc

124 n and ubiquitination of the receptor along a proteosome/lysosome-mediated pathway.

125 events recruitment of the ubiquitylation/19S proteosome machinery that normally mediates the signal-d

126 recognition and destruction by the ubiquitin/proteosome machinery.

127 rotein degradation mediated by the ubiquitin-proteosome machinery.

128 se that acts on STAT proteins to cause their proteosome-mediated degradation and enhance their dephos

129 ed on the hypothesis that ubiquitination and proteosome-mediated degradation of Nrf2 in the cytoplasm

130 ndered the protein unstable and led to rapid proteosome-mediated degradation, a feature that was more

131 thway because the mdm2 protein marks p53 for proteosome-mediated degradation, thereby providing a neg

132 not that from genotype 1, targets NAP1L1 for proteosome-mediated degradation.

133 due to ubiquitination of beta-arrestin-1 and proteosome-mediated degradation.

134 , blocking DNA binding and targeting p53 for proteosome-mediated degradation.

135 isfolding, endoplasmic reticular stress, and proteosome-mediated degradation.

136 lates beta-catenin, leading to its ubiquitin-proteosome-mediated degradation.

137 oline hydroxylation, earmarking HIFalpha for proteosome-mediated degradation.

138 These enzymes usually are involved in proteosome-mediated degradation; however, our data sugge

139 and 119 (alpha-syn119), two products of 20S proteosome-mediated endoproteolytic cleavage.

140 However, SopE is rapidly degraded through a proteosome-mediated pathway, while SptP exhibits much sl

141 to UV irradiation reduced CtBP levels via a proteosome-mediated pathway.

142 cated that the decrease is through ubiquitin-proteosome-mediated proteolysis.

143 These data expand the applicability of the proteosome mucosal vaccine delivery system to protein to

144 al development of triterpenoid dual-function proteosome/NF-kappaB inhibitors as therapeutics for huma

145 hanisms that characterize the effect of MOMP proteosomes on host cells may provide new insights for i

146 specificity caspase inhibitor but not by the proteosome or calpain inhibitor.

147 Multiple myeloma is exquisitely sensitive to proteosome or NF-kappaB pathway inhibition.

148 egradation of cofilin through ubiquitination-proteosome pathway and consequently inhibits cofilin act

149 lective protein degradation by the ubiquitin-proteosome pathway has recently emerged as a powerful re

150 signal, but its destruction by the ubiquitin-proteosome pathway is required to allow the cell to cont

151 to further investigate whether the ubiquitin-proteosome pathway responsible for cyclin B degradation

152 iates degradation of RON through a ubiquitin-proteosome pathway, and suggest that by targeting signal

153 and phosphatases, components of a ubiquitin-proteosome pathway, and transcriptional regulators.

154 oupled with the inactivity-induced atrogin-1/proteosome pathway, leads to the acute muscle loss seen

155 reticulum can be regulated by the ubiquitin-proteosome pathway, resulting in altered surface express

156 cell epitopes are generated in the ubiquitin-proteosome pathway, we also investigated the ability of

157 r remodeling pathways, such as the ubiquitin-proteosome pathway, were severely disrupted.

158 isplay increased activities of the ubiquitin-proteosome pathway, which degrades cyclin B, as compared

159 et proteins for degradation in the ubiquitin-proteosome pathway.

160 level is tightly controlled by the ubiquitin-proteosome pathway.

161 onal ZTL, and is prevented by inhibiting the proteosome pathway.

162 in Arabidopsis by SON1 through the ubiquitin-proteosome pathway.

163 pha(o) is predominantly degraded through the proteosome pathway.

164 ase, followed by degradation via a ubiquitin-proteosome pathway.

165 n of cofilin and its degradation through the proteosome pathway.

166 and proceeds via the ubiquitin-dependent 26S proteosome pathway.

167 otein stability of the 9-1-1 complex via the proteosome pathway.

168 are induction of myofiber-specific ubiquitin/proteosome pathways (eg, atrogin-1).

169 h activation of macroautophagy and ubiquitin-proteosome pathways.

170 p160 with MPL-AF, proteosomes, emulsomes, or proteosomes plus emulsomes elicited HIV-1MN-neutralizing

171 formulations with proteosomes, emulsomes, or proteosomes plus emulsomes elicited HIV-1MN-neutralizing

172 ed with liposomes plus MPL, proteosomes, and proteosomes plus emulsomes.

173 s likely to be driven by slow binding to the proteosome present in red blood cells.

174 By inhibiting both IKK and the proteosome, pristimerin causes overt suppression of cons

175 an unstable protein that is targeted to the proteosome, probably by Scul(Cdc4)-mediated ubiquitinati

176 otype results from a defect in the ubiquitin-proteosome protein degradation pathway.

177 ription factors, antioxidants, and ubiquitin proteosome proteins.

178 tion of critical components of the ubiquitin proteosome proteolytic (UPP) pathway.

179 and suggest a possible link of the ubiquitin/proteosome proteolytic pathway and the WT1 transcription

180 e induced after intranasal immunization with proteosome-rgp160 delivered either in saline or with emu

181 olera toxin B subunit (CTB) was added to the proteosome-rgp160 vaccine.

182 estinal, and fecal IgA and IgG by intranasal proteosome-rgp160 vaccines delivered in saline or with e

183 mmune responses to intranasally administered proteosome-S. flexneri 2a LPS vaccine is similar to thos

184 t immunization of nonhuman primates with the proteosome-SEB toxoid vaccine is safe, immunogenic, and

185 The proteosome-SEB toxoid vaccine was efficacious by both ro

186 cy of SEB toxoid indicates that testing such proteosome-SEB toxoid vaccines in the nonhuman primate a

187 enteral and respiratory vaccination with the proteosome-SEB toxoid, thereby supporting clinical trial

188 grity by activating a Calcineurin-FoxO-MuRF1-proteosome signaling pathway.

189 use of inhibitors, including lactacystin (a proteosome-specific inhibitor), suggests that Galpha(o)

190 t the functional segment of the human Psmd12 proteosome sub-unit contains a PINT domain.

191 nd LC3 co-localization without activation of proteosome, suggesting a novel Mfn2 degradation pathway

192 uld be detected only after inhibition of the proteosome, suggesting that BOS1 is a target of ubiquiti

193 nhibited by lactacystin, an inhibitor of 26S proteosome, suggesting that curcumin represses cyclin D1

194 e ubiquitin E2 UBC4, or by inhibition of the proteosome suppresses mot1-301 mutant phenotypes and inc

195 egraded by the Fizzy-related-APC/C ubiquitin proteosome system during the endocycle.

196 dence indicates a critical role of ubiquitin-proteosome system in apoptosis regulation.

197 degradation (t(1/2) < 5 min) of PIF5 via the proteosome system upon irradiation.

198 macrophages, up-regulation of the ubiquitin-proteosome system, and down-regulation of the helix-loop

199 lure of protein degredation by the ubiquitin-proteosome system, production of neurotoxic peptide olig

200 elerate protein degradation by the ubiquitin-proteosome system.

201 ted degradation (ERAD) through the ubiquitin proteosome system.

202 ll prior to its degradation via the ubiqitin-proteosome system.

203 y to be independent of the lysosomal and the proteosome systems.

204 r subunits in neurons by drawing them to the proteosome, thus regulating nicotine-induced up-regulati

205 The capacity of proteosomes to enhance both i.m. and intranasal immunoge

206 Furthermore, proteosome-toxoid delivered intranasally in saline or i.

207 Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine s

208 Proteosome-toxoid plus alum given i.m. also elicited mor

209 n, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-S

210 f2 for ubiquitination and degradation by the proteosome under basal culture conditions.

211 al and systemic IgA and IgG responses by the proteosome vaccine delivered by a respiratory route are

212 ids and suggest that respiratory delivery of proteosome vaccines may be practical for enhancement of

213 g for the development of mucosally delivered proteosome vaccines to protect against SEB and other tox

214 Substrate hydrolysis by lysosomes or proteosomes was controlled for using NH(4)Cl and clasto-

215 . immunization with toxoid in saline without proteosomes was not significantly protective in either c

216 Using MOMP formed in pure protein micelles (proteosomes), we show the induction of TLR2-dependent in

217 whereas inhibitors of prolyl hydroxylases or proteosome were ineffective.

218 and blocked by an inhibitor (mg-132) of the proteosome which mediates NF-kappabeta activation.

219 A (MPL), MPL-AF, proteosomes, emulsomes, or proteosomes with emulsomes elicited strong gp160-specifi